Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATAI 
ATAI Life Sciences BV (ATAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ATAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.21% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 491.04M USD | Price to earnings Ratio - | 1Y Target Price 8.8 |
Price to earnings Ratio - | 1Y Target Price 8.8 | ||
Volume (30-day avg) 2595724 | Beta 1.48 | 52 Weeks Range 1.03 - 2.64 | Updated Date 06/19/2025 |
52 Weeks Range 1.03 - 2.64 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1239.23% |
Management Effectiveness
Return on Assets (TTM) -26.04% | Return on Equity (TTM) -79.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 419502450 | Price to Sales(TTM) 263.57 |
Enterprise Value 419502450 | Price to Sales(TTM) 263.57 | ||
Enterprise Value to Revenue 225.18 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 210746000 | Shares Floating 111215420 |
Shares Outstanding 210746000 | Shares Floating 111215420 | ||
Percent Insiders 8.22 | Percent Institutions 33.4 |
Analyst Ratings
Rating 4.71 | Target Price 8 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ATAI Life Sciences BV
Company Overview
History and Background
ATAI Life Sciences BV was founded in 2018 as a biopharmaceutical company aiming to transform mental healthcare through innovative therapies. It has grown by acquiring and investing in companies focused on psychedelic and non-psychedelic compounds for mental health disorders.
Core Business Areas
- Drug Development: Focuses on discovering, developing, and commercializing therapies for mental health disorders, including depression, anxiety, and addiction.
- Platform Investments: Invests in and supports various companies with promising mental health treatment approaches, providing funding and resources.
Leadership and Structure
The company is led by Florian Brand (CEO) and has a structured organizational model focusing on both internal drug development programs and external investments. Board members include prominent figures in venture capital and biotech.
Top Products and Market Share
Key Offerings
- PCN-101 (R-ketamine): A potential treatment for treatment-resistant depression (TRD). Phase 2 data is available. Market share data is not yet applicable due to it still being in trials, however, key competitors include Johnson & Johnson (SPRAVATO) and newer entrants developing novel ketamine analogs.
- RL-007: A potential treatment for cognitive impairment associated with schizophrenia (CIAS). Phase 2b data is available. Market share data is not applicable due to it still being in trials. Competitors include pharmaceutical companies developing cognitive enhancers for schizophrenia, like Cerevel Therapeutics.
Market Dynamics
Industry Overview
The mental health market is growing rapidly, driven by increasing awareness, prevalence, and unmet needs. There is a surge of interest in psychedelic-assisted therapies and other innovative treatments. Regulations are evolving.
Positioning
ATAI Life Sciences is positioned as a leader in the development of innovative mental health therapies, particularly those involving psychedelic and psychedelic-inspired compounds. They have a diverse portfolio of investments.
Total Addressable Market (TAM)
The global mental health market is estimated to be over $100 billion. ATAI is targeting various segments within this, including depression, anxiety, and schizophrenia. Their positioning allows them to address a large portion of the TAM if their therapies are approved and adopted.
Upturn SWOT Analysis
Strengths
- Diverse portfolio of drug candidates
- Strong financial backing
- Experienced leadership team
- Focus on innovative therapies
Weaknesses
- High cash burn rate
- Regulatory hurdles and uncertainty
- Dependence on clinical trial outcomes
- Novelty of psychedelic therapies may limit adoption.
Opportunities
- Growing market for mental health treatments
- Potential for breakthrough therapies
- Partnerships with pharmaceutical companies
- Expansion into new indications
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Negative perceptions of psychedelic therapies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- JNJ
- LYRA
- GHRS
Competitive Landscape
ATAI differentiates itself through its focus on psychedelic and psychedelic-inspired therapies. JNJ has strong market presence through already approved drug. LYRA is a digital mental health player. All three companies are in the mental health market but take different approaches.
Major Acquisitions
Perception Neuroscience
- Year: 2020
- Acquisition Price (USD millions): 20.7
- Strategic Rationale: Expanded ATAI's pipeline with PCN-101 (R-ketamine) for treatment-resistant depression.
Growth Trajectory and Initiatives
Historical Growth: Since its founding in 2018, growth has been driven by strategic acquisitions and investments in promising mental health therapies. There is no historical revenue to show.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely, but generally anticipate revenue growth in the coming years if products receive regulatory approval.
Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, and continuing to evaluate new investment opportunities.
Summary
ATAI Life Sciences is a high-risk, high-reward company focused on innovative mental health therapies, particularly psychedelics. It is positioned in a rapidly growing market but faces significant regulatory and clinical development challenges. While it boasts a diverse portfolio and strong financial backing, it is pre-revenue and reliant on successful clinical trial outcomes. Investors should carefully consider the speculative nature of this stock, given the novelty of the approach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ATAI Life Sciences BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-18 | Co-Founder & CEO Dr. Srinivas G. Rao M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://atai.com |
Full time employees 54 | Website https://atai.com | ||
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.